Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Jacqueline M McBride - Senior Scientist, OMNI Biomarker Development

Jacqueline M McBride

Senior Scientist, OMNI Biomarker Development

"Imagination is more important than knowledge"
Years at Genentech
Awards & Honors

I am native Scot and Basic Immunologist. I began my science career at the university of Glasgow in one of the first Immunology degree courses offered in the UK. I continued to grow my passion for science in Europe at the IMP Biocenter in Vienna looking to understand the mechanisms of dendritic cell tolerance. From here I sought to expand my knowledge in Clinical Immunology at Stanford School of medicine and then joined the postdoctoral program at Genentech in Immunology discovery. I soon realized my passion and curiosity was in biotechnology and translational science and joined the OMNI-Biomarker development group in Development Sciences as a Scientist. I currently work as a Scientist and a Biomarker Subteam leader and supporting the development of novel therapeutics such as Influenza A, Etrolizumab, and anti- PD-L1 combos.

Featured Publication

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

Arthritis Rheum. 2012 Nov;64(11):3666-76.

McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J.